[Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes].

Incorporación de resultados informados por pacientes con psoriasis y dermatitis atópica en las consultas de atención farmacéutica y dermatología: herramienta que mejora la calidad asistencial y resultados en salud.
Atopic dermatitis Dermatitis atópica Health outcomes Patient satisfaction Patient-reported outcomes Psoriasis Resultados en salud Resultados reportados por los pacientes Satisfacción del paciente

Journal

Journal of healthcare quality research
ISSN: 2603-6479
Titre abrégé: J Healthc Qual Res
Pays: Spain
ID NLM: 101735273

Informations de publication

Date de publication:
31 Oct 2023
Historique:
received: 03 10 2022
revised: 17 01 2023
accepted: 04 10 2023
medline: 3 11 2023
pubmed: 3 11 2023
entrez: 2 11 2023
Statut: aheadofprint

Résumé

Patient-reported outcomes (PROs) provide subjective information about their disease, treatment, and quality of life. To introduce a new system of work coordinated between pharmacists and dermatologists, based on the collection and analysis of PROs to assess its clinical impact as well as patients satisfaction. A prospective single-centre observational study was conducted under clinical conditions and included adult patients diagnosed with psoriasis (PS) and atopic dermatitis (AD) between April-2021 and February-2022. Pharmacists and dermatologists agreed on this systematic work. A REDCap® database was designed to facilitate data collection and the subsequent analysis. A total of 288 and 41 patients with PS and AD, respectively, were included. Those who started treatment showed significant improvement with a decrease in PROs and clinical parameters (p < 0.001). The pharmacist made 168 and 7 recommendations to dermatologists for PS and AD patients, respectively, of which 66.07% and 57.1% were accepted. The most common recommendations were «consult with rheumatologist» (20.83%), «extend drug regimen» (19.64%) and «consider change in treatment» (11.90%). Adverse events were reported in 55 and 17 patients with PS and AD, respectively. Of 103 patients, 75% were «very satisfied» and 20% «satisfied» with the system. This new working system helps to evaluate the short and long-term effectiveness of treatments and also to identify adverse events, alarm symptoms and co-morbidities in order to optimize therapies. Collaboration between pharmacists and dermatologists reduces decision-making time and patients appreciate better clinical care leading to higher patient satisfaction.

Identifiants

pubmed: 37919175
pii: S2603-6479(23)00062-3
doi: 10.1016/j.jhqr.2023.10.004
pii:
doi:

Types de publication

English Abstract Journal Article

Langues

spa

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 FECA. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

M Á González-Fernández (MÁ)

Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España. Electronic address: mariaangeles.gonzalez.fernandez@salud.madrid.org.

P Herranz-Pinto (P)

Servicio de Dermatología. Hospital Universitario La Paz, Madrid, España.

M L Alonso-Pacheco (ML)

Servicio de Dermatología. Hospital Universitario La Paz, Madrid, España.

C Mateo-Salillas (C)

Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España.

Á Hoyo-Muñoz (Á)

Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España.

I Jiménez-Nácher (I)

Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España.

F Moreno-Ramos (F)

Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España.

A Herrero-Ambrosio (A)

Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España.

Classifications MeSH